Your session is about to expire
← Back to Search
Immunotoxin
Immunotoxin for Non-Hodgkin's Lymphoma (NHL Trial)
Phase 1
Waitlist Available
Research Sponsored by Cambridge Antibody Technology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Must have failed at least two or more courses of prior standard chemotherapy and/or biologic therapy
Patients with indolent subtypes of CD22+ B-cell non-Hodgkin's lymphoma at stage III-IV
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
NHL Trial Summary
This trial is testing a new immunotoxin to treat Non-Hodgkin's lymphoma that has not responded to other treatments.
Who is the study for?
This trial is for patients with B-cell non-Hodgkin's lymphoma who haven't responded to at least two standard treatments. They must have measurable disease, CD22-positive malignancy, and a life expectancy of less than 6 months. Exclusions include those with bone marrow transplants, certain organ dysfunctions, recent therapies, or positive HIV/Hepatitis B.Check my eligibility
What is being tested?
The study tests the maximum tolerated dose of CAT-8015 immunotoxin in patients with resistant Non-Hodgkin's lymphoma. It aims to see if this treatment can target and kill cancer cells without harming normal cells in a phase 1 dose escalation setup.See study design
What are the potential side effects?
Potential side effects may include reactions specific to the immunotoxin such as allergic responses or symptoms related to the toxin component affecting different organs. Since it's an early-phase trial determining safety, exact side effects will be monitored closely.
NHL Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have tried at least two standard cancer treatments without success.
Select...
I have a slow-growing type of B-cell non-Hodgkin's lymphoma in an advanced stage.
Select...
I have been diagnosed with B-cell non-Hodgkin's lymphoma that can be measured.
Select...
I am able to get out of my bed or chair and move around.
NHL Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Antineoplastic Agents
Secondary outcome measures
To assess the immunogenic potential of CAT-8015 to induce antibodies; To investigate the potential of biomarkers to predict any therapeutic or toxic response.
Find a Location
Who is running the clinical trial?
Cambridge Antibody TechnologyLead Sponsor
7 Previous Clinical Trials
259 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been cancer-free for less than 5 years.I have tried at least two standard cancer treatments without success.I have a slow-growing type of B-cell non-Hodgkin's lymphoma in an advanced stage.My liver function is mostly normal, except for high bilirubin due to Gilbert's disease.I haven't had recent treatments that would exclude me.I have had a bone marrow transplant.My lung function tests show less than half the expected values.I have been diagnosed with B-cell non-Hodgkin's lymphoma that can be measured.My cancer has spread to my brain or spinal cord.I agree to use birth control during the study.My kidney function is reduced with a creatinine clearance of 60 mL/min or less.My body has significant antibodies against CAT-8015 or CD22.My blood clotting issue is not severe unless it's because of my blood thinner medication.I do not have any uncontrolled illnesses causing symptoms.I am able to get out of my bed or chair and move around.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is enrollment for this clinical research currently open?
"This clinical trial, first posted on August 1st 2007 and last edited 8 days later, is no longer recruiting patients. However, according to the information sourced from clinicaltrials.gov there are presently 2842 other studies that are enrolling candidates."
Answered by AI
What potential dangers could be associated with this treatment?
"The safety of this novel therapy is estimated to be a 1 due its Phase 1 designation, indicating that there is only limited data backing both safety and efficacy."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger